Home › Therapeutic areas › GI/Hepatology › Eosinophilic Esophagitis

Eosinophilic Esophagitis (4 companies)

Companies with an active program in Eosinophilic Esophagitis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 1 Phase 2 $61.4M 9
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.36B 9
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 — 9